Assessment of orally dosed commercial silver nanoparticles on human ex vivo platelet aggregation

Nanotoxicology

Volumn 8, Issue 3, 2014, Pages 328-333

  Smock, Kristi J ^a   Schmidt, Robert L ^a   Hadlock, Greg ^b   Stoddard, Greg ^c   Grainger, David W ^b   Munger, Mark A ^b,c  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Biological activity; Blood; Nanoparticles; Nanotechnology; Nanotoxicology; Platelet aggregation; Silver

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; DILUENT; SILVER NANOPARTICLE;

ABSORPTION; ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISPERSION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; PARTICLE SIZE; PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TRANSMISSION ELECTRON MICROSCOPY;

ADENOSINE DIPHOSPHATE; ADMINISTRATION, ORAL; ADULT; ANIMALS; BLOOD PLATELETS; CELLS, CULTURED; COLLAGEN; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; METAL NANOPARTICLES; MIDDLE AGED; PLATELET AGGREGATION; SILVER; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84890331305     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.3109/17435390.2013.788749     Document Type: Article

References (38)

1. AHA Statistical Update 2012 Heart Disease and Stroke Statistics. 2012. A report from the American Heart Association. Circulation 125. e2- e220
2. Ahmad T, Voora D, Becker RC. 2011. The pharmacogenetics of antiplatelet agents: Towards personalized therapy? Clin Chimica Acta 8 (10):560-571
3. Alt V, Bechert T, Steinrucke P, et al. 2004. An in vitro assessment of the antibacterial properties and cytotoxicity of nanoparticulate silver bone cement. Biomaterials 25:4383-4391
4. Bosetti M, Masse A, Tobin E, Cannas M. 2002. Silver coated materials for external fixation devices: In vitro biocompatibility and genotoxicity. Biomaterials 23:887-892
5. Braydich-Stolle L, Hussain S, Schlager JJ, Hofmann MC. 2005. In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicol Sci 88(2):412-419
6. Buzea C, Pacheco II, Robbie K. 2007. Nanomaterials and nanoparticles: Sources and toxicity. Biointerphases 2:MR17-MR71
7. Cattaneo M, Hayward CPM, Moffat KA, Publiano MT, Liu Y, Michelson AD. 2009. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: A report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 7:1029
8. Christie DJ, Avari T, Carrington LR, et al. 2008. Platelet Function Testing by Aggregometry; Approved guideline. CLSI document H58-A 38(31):Wayne, PA, USA
9. Clinical and Laboratory Standards Institute. Clinical and Laboratory Standard Institute document H58-A. 2008. Platelet function testing by aggregometry; approved Guideline, Wayne PA, editors. Clin Lab Standards Institute
10. Dantam J, Zhu H, Stapleton FJ. 2011. Biocidal efficacy of silver impregnated contact lens storage cases. Invest Ophthalmol Vis Sci 52:51-57
11. Des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V. 2006. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Controll Release 116:1-27
12. Florence AT. 2007. Pharmaceutical nanotechnology: More than size. Ten topics for research. Int J Pharm 339:1-2
13. Fuentes EQ, Fuentes FQ, Andrés V, Pello OM, de Mora JF, Palomo IG. 2012. Role of platelets as mediators that link information and thrombosis in atherosclerosis. Platelets; Epub ahead of print
14. Geffers C, Gastmeier A, Schwab F, Groneberg K, Rüden H, Gastmeier P. 2010. Use of central venous catheter and peripheral venous catheter as risk factors for nosocomial bloodstream infection in very-low-birth-weight infants. Infect Control Hosp Epidemiol 31:395-401
15. Held C, Hjemdahl P, Rehnqvist N, et al. 1997. Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angian Prognosis Study in Stockholm (APSIS). A comparison with healthy controls. J Intern Med 241(1):59-69
16. Holladay RJ, Christensen H, Moeller WD, inventors. 1999. Apparatus and method for producing antimicrobial silver solution. United States Patent 6,214,299
17. Holladay RJ, Christensen H, Moeller WD, inventors. 2003. Treatment of humans with colloidal silver composition. United States Patent 7,135,195
18. Hussain H, Jaitley V, Florence AT. 2001. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 50:107-142
19. Jun E-AH, Lim K-M, Kim K, et al. 2011. Silver nanoparticles enhance thrombus formation through increased platelet aggregation and procoagulant activity. Nanotoxicology 5(2):157-167
20. Kim K-J, Sung WS, Suh BK, Moon SK, Choi J-S. 2009. Antifungal activity and mode of action of silver nano-particles on Candida albicans. Biometals 22(2):235-242
21. Margetic S. 2011. Inflammation and haemostatis. Biochem Med 22 (1):49-62
22. Mills NL, Donaldson K, Hadoke PW, et al. 2009. Adverse cardiovascular events of air pollution. Nat Clin Pract Cardiovasc Med 6:36-44
23. Munger MA, Radwansk P, Hadlock G, Stoddard G, Shaaban A, Falconer J, et al. 2013. In vivo human time-exposure study of orally dosed commercial silver nanoparticles. Nanomedicine; Revised Resubmitted
24. Muzi G, Locati EH, Murgia N, Ambrosio G, Abbritti G. 2004. Evaluation of the effects of occupational noxae on the cardiovascular system. Med Lav 95(2):146-157
25. O'Hagan DT. 1996. The intestinal uptake of particles and the implications for drug and antigen delivery. J Anal 189:477-482
26. Project on Emerging Nanotechnologies. 2012. Nanotech-enabled consumer products continue to rise. http//www.nanotechproject.org/ news/archive/9231/. Accessed on 14 June 2012
27. Roy R, Hoover MR, Bhalla AS, et al. 2007. Ultradilute Ag-Aquasols with extraordinary bactericidal properties: Role of the system Ag-0-H20. Mat Res Innov 11:3-18
28. Sabatier C, Ferrer R, Valles J. 2009. Treatment strategies for central venous catheter infections. Expert Opin Pharmacother 10:2231-2243
29. Santoro CM, Duchschere NL, Grainger DW. 2007. Antimicrobial efficacy and ocular cell toxicity from silver nanoparticles. NanoBiotechnology 3(2):55-65
30. Schleh C, Semmler-Behnke M, Lipka J, et al. 2012. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology 6(1):36-46
31. Shrivastava S, Bera T, Roy A, Singh G, Ramachandrarao P, Dash D. 2007. Characterization of enhanced antibacterial effects of novel silver nanoparticles. Nanotechnology 18:225103
32. Shrivastava S, Bera T, Singh SK, Singh G, Ramachandrarao P, Dash D. 2009. Characterization of antiplatelet properties of silver nanoparticles. ACS Nano 23(6):1357-1364
33. Stevens KN, Crespo-Biel O, van den Bosch EE, et al. 2009a. The relationship between the antimicrobial effect of catheter coatings containing silver nanoparticles and the coagulation of contacting blood. Biomaterials 30:3682-3690
34. Stevens KN, Knetsch ML, Sen A, Sambhy V, Koole LH. 2009b. Disruption and activation of blood platelets in contact with an antimicrobial composite coating consisting of a pyridinium polymer and AgBr nanoparticles. ACS Appl Mater Interfaces 1:2049-2054
35. Stevens KNJ, Croes S, Boersma RS, et al. 2010. Hydrophillic surface coatings with embedded biocidal silver nanoparticles and sodium heparin for central venous catheters. Biomaterials 32:1264-1269
36. Wang XD, Zhang DF, Liu XB, et al. 2012. Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance. Eur J Intern Med 23:148-53
37. Wright SP. 1992. Adjusted P-values for simultaneous inference. Biometrics 48:1005-1013
38. Xiu ZM, Zhang Q-B, Puppala HL, Colvin VL, Alvarez PJJ. 2012. Negligible particle-specific antibacterial activity of silver nanoparticles. Nano Lett 12:4271-4275